CANADA: Tilray Canada announced that it has entered into a Letter of Intent (LOI) to become a preferred medical cannabis supplier to Pharmasave, the premier independent pharmacy banner in Canada.
Subject to changes to Canadian regulations that would allow such distribution, Tilray will supply and distribute Good Manufacturing Practices (GMP) certified Tilray-branded medical cannabis products through Pharmasave pharmacists. Tilray is a global pioneer in medical cannabis research, cultivation, processing and distribution, and was the first medical cannabis company with a North American production facility to obtain GMP certification in accordance with the European Medicines Agency’s (EMA) standards. Tilray currently supplies tens of thousands of patients with high-quality, GMP-certified products in ten countries spanning five continents.
Pharmasave is a member-governed cooperative of more than 650 independently owned community pharmacies across Canada. Pharmasave believes that pharmacists play an important role in helping to improve patient care. For more than a year, Pharmasave has been providing Pharmasave Pharmacists, as medication management experts, with education and resources on medical cannabis, to help them better understand the current regulations and learn more about the possible uses, benefits and risks of medical cannabis. For those patients who take multiple medications and may have a complex medication therapy, pharmacists can work with patients and physicians to safely achieve positive health outcomes.
“Tilray’s products are available in ten countries around the world. Our products can be purchased by patients in pharmacies in each of those countries except Canada. Today’s announcement puts us in a strong position to expand the availability of our products to additional patients in need throughout Canada,” said Brendan Kennedy, Tilray CEO. “It’s exciting that we have the potential to bring our medical cannabis products to patients via pharmacies in Canada with a partner like Pharmasave, a company that shares our commitment to patient safety and access.”